{"id":20292,"date":"2011-04-09T10:15:16","date_gmt":"2011-04-09T14:45:16","guid":{"rendered":"http:\/\/piel-l.org\/blog\/?p=20292"},"modified":"2011-04-09T23:54:31","modified_gmt":"2011-04-10T04:24:31","slug":"aprobado-por-la-fda-ipilimumab-para-el-melanoma-metastasico","status":"publish","type":"post","link":"https:\/\/piel-l.org\/blog\/20292","title":{"rendered":"Aprobado por la FDA Ipilimumab para el Melanoma Metast\u00e1sico"},"content":{"rendered":"<p>El 25 de marzo de 2011, la FDA anunci\u00f3 la aprobaci\u00f3n del medicamento IPILIMUMAB para el tratamiento del melanoma metast\u00e1sico, les anexo el link del anuncio y el documento en pdf con la informaci\u00f3n que llevar\u00e1 el prospecto.<\/p>\n<p><!--more--><\/p>\n<p><strong>Link:<\/strong><\/p>\n<p><em>Press Announcements &gt; FDA approves new treatment for a type of late-stage skin cancer<\/em><a href=\"http:\/\/1.usa.gov\/hin7u5\" target=\"_blank\"> http:\/\/1.usa.gov\/hin7u5<\/a><\/p>\n<p><strong>Archivo adjunto:<\/strong><\/p>\n<p><a href=\"http:\/\/piel-l.org\/blog\/wp-content\/uploads\/\/2011\/04\/Ipilimumab-Melanoma-Metastasico-FDA.pdf\">Ipilimumab Melanoma Metastasico FDA.pdf<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>El 25 de marzo de 2011, la FDA anunci\u00f3 la aprobaci\u00f3n del medicamento IPILIMUMAB para el tratamiento del melanoma metast\u00e1sico, les anexo el link del anuncio y el documento en pdf con la informaci\u00f3n que llevar\u00e1 el prospecto.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"class_list":["post-20292","post","type-post","status-publish","format-standard","","category-farmacologia"],"_links":{"self":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/20292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/comments?post=20292"}],"version-history":[{"count":0,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/posts\/20292\/revisions"}],"wp:attachment":[{"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/media?parent=20292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/categories?post=20292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/piel-l.org\/blog\/wp-json\/wp\/v2\/tags?post=20292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}